Symbols

ELVN

Enliven·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 2

Consensus Rating "Strong Buy"

Ample Liquidity

RSI Overbought

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ELVN

Enliven Therapeutics, Inc.

A clinical-stage biopharmaceutical company developing new therapies to treat rare inherited hemoglobin diseases and other serious diseases

Industry

Pharmaceutical

Established Date

Listing Date

03/12/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.enliventherapeutics.com

Security Type

Common stock

Office address

6200 Lookout Road, Boulder, CO 80301

Business

Introduction

Enliven Therapeutics, Inc., was incorporated in Delaware in June 2019. This clinical-stage biopharmaceutical company focuses on the discovery and development of small molecule therapeutic drugs to help people not only live longer, but live better. The Company addresses existing and emerging unmet needs through a precision medicine approach that improves survival and enhances overall well-being. Its discovery process combines deep insights and differentiated chemistry on clinically proven biological targets with the goal of designing therapies that meet these unmet needs. By combining clinically validated targets and specific target product features with rigorous clinical trial design and regulatory strategies, we are committed to developing drugs that effectively meet unmet needs and increase the likelihood of clinical and commercial success. Currently, the company is advancing ELVN-001 and exploring multiple additional research stage opportunities consistent with its small molecule development strategy.

Company Financials

EPS

ELVN has released its 2025 Q4 earnings. EPS was reported at -0.48, versus the expected -0.46, missing expectations. The chart below visualizes how ELVN has performed over recent quarters, highlighting trends in earnings surprises.